The insider sales are de minimis relative to market cap and are clearly tied to option exercise programs. No bearish signal. Monitor the next 10-Q for any change in Tyvaso DPI growth trajectory or competitive dynamics in inhaled prostacyclins.
Price Chart
Executive Summary
Three top executives at United Therapeutics (CEO, CFO, General Counsel) executed option exercises and sold a portion of the resulting shares in the week following the company's Q1 2026 earnings release. Total open-market sales were $1.44M, or ~0.006% of the $24.2B market cap — a trivial amount relative to company size. The sales appear to be routine tax- and cash-management transactions tied to option exercises, not a signal of deteriorating fundamentals.
Key Financial Metrics
Key Facts
- Total open-market sales by 3 insiders: $1.44M (0.006% of market cap)
- CEO Martine Rothblatt sold 2,871 shares for $1.63M across 4 trades, but also exercised options on 38,000 shares (mostly non-cash)
- CFO James Edgemond sold 1,849 shares for $1.05M, while exercising options on 20,000 shares
- EVP Paul Mahon sold 80 shares for $46.6K, exercising options on 8,300 shares
- All sales occurred after the May 6 earnings release, which showed a 2% revenue decline and 15% net income decline YoY
- The cluster is 6 days post-earnings — insiders were cleared to trade after the public release of results
Financial Impact
Open-market sales of $1.44M represent 0.006% of $24.2B market cap — immaterial
Risk Factors
- Q1 revenue declined 2% YoY and net income fell 15% — continued erosion in Nebulized Tyvaso and Remodulin could pressure future results
- Cost of sales surged 44% YoY, partly due to a $26.8M inventory reserve from a commercial supply agreement
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1778621182895 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $500.35 $497.31 | ▼ −0.61% | ▼ −2.72% | $552.73 (+10.47%) |
Sep 11, 2026 21d ago | Insider Cluster | $497.11 $494.63 | ▼ −0.50% | ▼ −0.28% | $552.73 (+11.19%) |
Sep 10, 2026 22d ago | Insider Cluster | $503.86 $497.27 | ▼ −1.31% | ▼ −0.81% | $552.73 (+9.70%) |
Sep 9, 2026 23d ago | Insider Cluster | $506.82 $498.48 | ▼ −1.65% | ▼ −0.99% | $552.73 (+9.06%) |
Sep 4, 2026 28d ago | Insider Cluster | $487.61 $502.70 | ▲ +3.09% | ▲ +4.30% | $552.73 (+13.36%) |
Sep 3, 2026 29d ago | Insider Cluster | $488.16 $497.11 | ▲ +1.83% | ▲ +2.98% | $552.73 (+13.23%) |
Aug 28, 2026 5w ago | Insider Cluster | $515.46 $487.61 | ▼ −5.40% | ▼ −5.51% | $552.73 (+7.23%) |
Aug 27, 2026 5w ago | Insider Cluster | $527.91 $492.02 | ▼ −6.80% | ▼ −6.03% | $552.73 (+4.70%) |
Aug 26, 2026 5w ago | Insider Cluster | $516.68 $492.02 | ▼ −4.77% | ▼ −4.65% | $552.73 (+6.98%) |
Aug 25, 2026 5w ago | Insider Cluster | $516.68 $492.02 | ▼ −4.77% | ▼ −4.65% | $552.73 (+6.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access